Tyrosine kinase inhibitors;Les inhibiteurs de tyrosine kinase

Bulletin du Cancer

Volumn 98, Issue 11, 2011, Pages 1321-1334

  Robert, Jacques ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; Cell proliferation; EGFR; PDGFR; Tyrosine kinase; VEGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CRYSTALLOGRAPHY; HUMAN; ONCOLOGY; PATIENT ATTITUDE; PROTEIN INTERACTION; REVIEW;

EID: 82455188578     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1472     Document Type: Review

References (34)

1. Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008; 7 : 391-7. (Pubitemid 351619111)
2. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4 : 361-70. (Pubitemid 38579482)
3. Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009; 8 : 709-23.
4. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10 : 130-7.
5. Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 2010; 11 : 60-74.
6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9 : 28-39.
7. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358 : 1160-74.
8. Hammerman PS, Jänne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15 : 7502-9.
9. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5 : 341-54. (Pubitemid 40637826)
10. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21 : 177-84.
11. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26 : 1742-51.
12. PaoW, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10 : 760- 74.
13. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008; 59 : 429-42. (Pubitemid 351287947)
14. Vivanco I, Mellinghoff IK. Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 2010; 22 : 573-8.
15. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10 : 116-129.
16. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8 : 235-53.
17. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16 : 2512-7.
18. Chaves J, Saif MW. IGF system in cancer: from bench to clinic. Anticancer Drugs 2011; 22 : 206-12.
19. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008; 14 : 6364-70.
20. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28 : 3009-21.
21. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010; 46 : 1260-70.
22. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009; 280 : 1-14.
23. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010; 18 : 548-51.
24. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011; 17 : 2081-6.
25. Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010; 116 : 5126-37.
26. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009; 15 : 7510-7518.
27. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116 : 5089-102.
28. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010; 16 : 5936-41.
29. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009; 15 : 7119-23.
30. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112 : 4808-17.
31. Quintás-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6 : 834-48. (Pubitemid 47500507)
32. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16 : 3526-32.
33. Pardanani A, Tefferi A.Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011; 18 : 105-10.
34. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10 : 127-40.